Monte Rosa’s $100M offering; Alexion to hand back preclinical program to Zealand Pharma

Plus, news about First Wave BioPharma:

Monte Rosa’s $100M offering: The molecular glue degrader biotech priced the offering at $4.70 per share $GLUE and expects it to close on May 20. At the end of March, it had enough cash and equivalents to take the biotech into the first half of 2026. — Kyle LaHucik

Alexion drops Zealand Pharma’s complement drug: The Danish biotech said AstraZeneca’s rare disease unit stopped developing Zealand’s preclinical complement C3 inhibitor, ZP10068, for “business reasons.” Alexion plans to hand the program back to Zealand. — Ayisha Sharma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Don’t write off MDMA yet: How the FDA got on board with psychedelics

Days after an advisory committee resoundingly voted for the Food and Drug Administration to reject MDMA as medical treatment, the founder of the company that

June 28, 2024

Long-term acute care hospital closures may have unintended consequences for patient care

Long-term acute care hospitals (LTCHs) are common sites of post-acute care for patients recovering from severe respiratory failure requiring long-term mechanical ventilation.

November 21, 2023

FemTech: Midi Health Secures $60M to Expand Virtual Clinic for Perimenopause and Menopause

Midi Health Founders, From left: CEO Joanna Strober, COO Sharon Meers, Chief Medical Officer Kathleen Jordan, MD, Chief Brand Officer Jill Herzig What You Should

April 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.